Table 1.
Therapeutic application targeting MQC to attenuate IR injury.
Therapies | Mechanisms | References |
---|---|---|
Dapagliflozin | Improve left ventricular function | Lahnwong et al., 2020 [122] |
Melatonin | Improve PPARγ expression | Zhou et al., 2017 [123] |
Istaroxime | Stimulate SERCA to dilate blood vessels and decrease ROS production | Hasenfuss et al., 2011 [125] |
SS31-Mito | Enhance LVEF and energy integrity with higher PGC-1α and Cyt c | Lee et al., 2018 [127] |